Phase 2 N=42 Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Acute Myeloid Leukemia
Primary: Safety and Tolerability — 42; 3; 3; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=135 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
Phase 2 N=7 A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Malignant Melanoma
Primary: Tolerability Evaluated by NCI CTCAE v5.0 — 52; 130; 6; 11 Number of Events
Phase 2 N=6 CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)
Radiculopathy
Primary: Change in Opioid Analgesic Plasma Levels — 10.86; -11.4 ng/mL
Phase 2 N=30 IVIG (Gamunex-C) Treatment Study for POTS Subjects
Postural Tachycardia Syndrome
Primary: Change in Symptoms Measured by Change in COMPASS-31 Score (After Initial Treatment Phase) — -5.5; -10.6 score on a scale — p=0.629
Phase 2 N=126 Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 12.6; 13.2; 9.5 Months
Phase 2 N=103 A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
Indolent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) According to the 2007 Revised International Working Group (IWG) Criteria — 65.3; 52.9; 62.2; 54.3 percentage of participants
Phase 2 N=16 Probiotics, Immune Function, and the Brain in Alcohol Consumers
Alcohol; Use, Problem
Primary: Lipopolysaccharide Binding Protein (LBP) — 23609.2; 28111.9 ng/ml — p=0.1183
Phase 2 N=273 A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 of the Double-blind Treatment Period — -1.9; -1.6; -2.1; -3.9 Units…
Phase 2 N=74 Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Osteoarthritis, Knee
Primary: Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — 28; 33 Participants — p=>0.9
Phase 2 N=54 A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B, Chronic
Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping All Study Interventions at the End of…
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
Phase 2 N=98 Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Mild Cognitive Impairment · MCI · Aging
Primary: fMRI Measurement — 2267.0; 1491.23; 673.31; 989.19 voxels
Phase 2 N=4 To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Myelofibrosis · Polycythemia Vera · Thrombocythemia
Primary: Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4 Participants
Phase 2 N=137 A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
COVID-19 · SARS-CoV-2 Infection
Primary: The Number and Percentage of Participants in Each Treatment Group With at Least One Serious Adverse Event (SAE) or Adverse Events of Special Interest (AESIs) — 0; 2; 2…